A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer. READ MORE
A recent phase III trial demonstrated that initial therapy with an immuno-agent improves PFS in patients with HR+, HER2- breast cancer.
A recent study found that 29% of breast cancer clinical trials are not comprised of control arms consistent with the current standard of care.
A recent survey found that 90% of patients treated with radiation therapy for breast cancer found their experiences to be less “scary” than anticipated.
Breast cancer surgeons play a big role in deciding whether women with early-stage breast cancer undergo a controversial operation to have both breasts removed, even when cancer is found in only one.
Research in Review
Patients with human epidermal growth factor 2 (HER2)-positive breast cancer who undergo induction chemotherapy are likely to convert to HER2-negative disease if residual disease occurs, prompting further systemic therapy.
Patients with human epidermal growth factor receptor 2-positive breast cancer benefit from an estimated 7 additional months of survival if treated with trastuzumab emtansine rather than the physician’s choice of therapy.
A radiation schedule half the standard course is as safe and effective for patients with breast cancer following a mastectomy.
MRI results after percutaneous biopsy for ductal carcinoma in situ often overestimate the extent of breast cancer, resulting in unnecessary mastectomies.
Researchers from Denmark followed a group of women diagnosed with breast cancer to compare breast conserving therapy with mastectomy.
Investigators examined potential biomarkers for the breast cancer gene GATA3 to see if any could be associated with patients’ survival.
Researchers evaluated bone health surveillance patterns, bone density outcomes, and fracture risk after salpingo-oophorectomy.
Presenters called for new ways to evaluate the success of novel agents for the treatment of breast cancer.